![Samantha Truex](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Samantha Truex
Directeur/Membre du Conseil chez AVALO THERAPEUTICS, INC.
Profil
Samantha Truex is currently the Director at Artios Pharma Ltd.
and the Independent Director at Avalo Therapeutics, Inc. She previously held positions as the Chief Executive Officer at Quench Bio, Inc. and Upstream Bio, Inc. She also served as the Director at HotSpot Therapeutics, Inc. and the Vice President-Corporate Development at Biogen, Inc. from 2010 to 2014.
Ms. Truex was the Chief Business Officer at Padlock Therapeutics, Inc. and the Chief Operating Officer at Synlogic Therapeutics from 2016 to 2017.
She has a background in education, having obtained an undergraduate degree from Dartmouth College in 1992, an MBA from Tuck School of Business at Dartmouth in 1995, and an undergraduate degree from Thayer School of Engineering At Dartmouth in 1993.
Postes actifs de Samantha Truex
Sociétés | Poste | Début |
---|---|---|
AVALO THERAPEUTICS, INC. | Directeur/Membre du Conseil | 28/03/2024 |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 15/06/2022 |
Anciens postes connus de Samantha Truex
Sociétés | Poste | Fin |
---|---|---|
Synlogic Therapeutics | Directeur des opérations | 30/06/2017 |
BIOGEN INC. | Directeur/Membre du Conseil | 01/04/2010 |
SANOFI | Directeur/Membre du Conseil | 31/12/2006 |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Directeur Général | - |
Atlas Venture Advisors, Inc.
![]() Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consultant / Advisor | - |
Formation de Samantha Truex
Dartmouth College | Undergraduate Degree |
Thayer School of Engineering At Dartmouth | Undergraduate Degree |
Tuck School of Business at Dartmouth | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
SANOFI | Health Technology |
BIOGEN INC. | Health Technology |
AVALO THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 7 |
---|---|
Padlock Therapeutics, Inc.
![]() Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | Health Technology |
Quench Bio, Inc.
![]() Quench Bio, Inc. BiotechnologyHealth Technology Quench Bio, Inc. develops therapies targeting innate immune pathways to treat life-threatening auto-immune and inflammatory diseases. The company was founded by Mark J. Tebbe, Mike Nolan, and Arturo Zychlinsky and is headquartered in Cambridge, MA. | Health Technology |
Atlas Venture Advisors, Inc.
![]() Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Artios Pharma Ltd.
![]() Artios Pharma Ltd. Pharmaceuticals: MajorHealth Technology Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Upstream Bio, Inc.
![]() Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Commercial Services |
Synlogic Therapeutics |